WO2002028440B1 - Procedes et compositions servant a moduler l'activation des lymphocytes t et leurs utilisations - Google Patents

Procedes et compositions servant a moduler l'activation des lymphocytes t et leurs utilisations

Info

Publication number
WO2002028440B1
WO2002028440B1 PCT/US2001/030864 US0130864W WO0228440B1 WO 2002028440 B1 WO2002028440 B1 WO 2002028440B1 US 0130864 W US0130864 W US 0130864W WO 0228440 B1 WO0228440 B1 WO 0228440B1
Authority
WO
WIPO (PCT)
Prior art keywords
ncam
fragment
antagonist
mammal
functional derivative
Prior art date
Application number
PCT/US2001/030864
Other languages
English (en)
Other versions
WO2002028440A1 (fr
Inventor
Anthony Montgomery
Larissa Balaian
Original Assignee
Scripps Research Inst
Anthony Montgomery
Larissa Balaian
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst, Anthony Montgomery, Larissa Balaian filed Critical Scripps Research Inst
Priority to AU2002213001A priority Critical patent/AU2002213001A1/en
Priority to JP2002532264A priority patent/JP2004531457A/ja
Priority to EP01981352A priority patent/EP1328298A4/fr
Priority to CA002423436A priority patent/CA2423436A1/fr
Publication of WO2002028440A1 publication Critical patent/WO2002028440A1/fr
Publication of WO2002028440B1 publication Critical patent/WO2002028440B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1777—Integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

L'invention concerne de façon générale le domaine de l'immunologie ou de la neuroimmunologie. Elle concerne, en particulier, un procédé servant à diminuer ou à inhiber l'activation des lymphocytes T et consistant à administrer une quantité efficace d'un antagoniste de NCAM L1 à un mammifère nécessitant la diminution ou l'inhibition de l'activation des lymphocytes T, ce qui permet de diminuer ou d'inhiber l'activation des lymphocytes T chez ledit mammifère. Elle concerne, de plus, des combinaisons et des procédés combinés servant à moduler l'activation des lymphocytes T. Elle concerne également un procédé servant à potentialiser l'activation des lymphocytes T et consistant à administrer une quantité efficace d'une molécule d'adhérence aux cellules neurales multimérisée L1 (NCAM L1) ou un de ses dérivés ou fragments fonctionnels, ou un acide nucléique codant L1 ou ledit dérivé fonctionnel ou ledit fragment, ou un agent amplifiant la production et/ou la fonction de stimulation combinée dudit L1 à un mammifère nécessitant l'activation des lymphocytes T, ce qui permet de potentialiser l'activation des lymphocytes T chez ledit mammifère.
PCT/US2001/030864 2000-10-02 2001-10-02 Procedes et compositions servant a moduler l'activation des lymphocytes t et leurs utilisations WO2002028440A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2002213001A AU2002213001A1 (en) 2000-10-02 2001-10-02 Methods and compositions for modulating T cell activation and uses thereof
JP2002532264A JP2004531457A (ja) 2000-10-02 2001-10-02 Ｔ細胞活性化を調節するための方法および組成物ならびにそれらの使用
EP01981352A EP1328298A4 (fr) 2000-10-02 2001-10-02 Procedes et compositions servant a moduler l'activation des lymphocytes t et leurs utilisations
CA002423436A CA2423436A1 (fr) 2000-10-02 2001-10-02 Procedes et compositions servant a moduler l'activation des lymphocytes t et leurs utilisations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23755500P 2000-10-02 2000-10-02
US60/237,555 2000-10-02

Publications (2)

Publication Number Publication Date
WO2002028440A1 WO2002028440A1 (fr) 2002-04-11
WO2002028440B1 true WO2002028440B1 (fr) 2002-05-30

Family

ID=22894231

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/030864 WO2002028440A1 (fr) 2000-10-02 2001-10-02 Procedes et compositions servant a moduler l'activation des lymphocytes t et leurs utilisations

Country Status (5)

Country Link
EP (1) EP1328298A4 (fr)
JP (1) JP2004531457A (fr)
AU (1) AU2002213001A1 (fr)
CA (1) CA2423436A1 (fr)
WO (1) WO2002028440A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3292152A1 (fr) 2015-05-07 2018-03-14 Agenus Inc. Anticorps anti-ox40 et procédés d'utilisation de ceux-ci
JP7089470B2 (ja) 2015-12-02 2022-06-22 アジェナス インコーポレイテッド 抗体およびその使用方法
EP3538152A4 (fr) 2016-11-09 2020-09-30 Agenus Inc. Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation

Also Published As

Publication number Publication date
EP1328298A4 (fr) 2005-05-04
WO2002028440A1 (fr) 2002-04-11
AU2002213001A1 (en) 2002-04-15
EP1328298A1 (fr) 2003-07-23
CA2423436A1 (fr) 2002-04-11
JP2004531457A (ja) 2004-10-14

Similar Documents

Publication Publication Date Title
Krueger The immunologic basis for the treatment of psoriasis with new biologic agents
Jullien et al. T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva™): mechanisms of action
Anderson et al. Phagocytosis mediated by three distinct Fc gamma receptor classes on human leukocytes.
Kearney et al. Antigen-dependent clonal expansion of a trace population of antigen-specific CD4+ T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4.
US6764681B2 (en) Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US6162432A (en) Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
Thomas et al. Functional differentiation of dendritic cells in rheumatoid arthritis: role of CD86 in the synovium.
Sidorenko et al. Characterization of a cell surface glycoprotein IPO-3, expressed on activated human B and T lymphocytes.
Genestier et al. Induction of Fas (Apo-1, CD95)-mediated apoptosis of activated lymphocytes by polyclonal antithymocyte globulins
CA2802344C (fr) Anticorps di-specifiques anti-tim-3 et pd-1 pour immunotherapie dans des etats pathologiques immuns chroniques
US5948893A (en) Murine hybridoma and antibody binding to CD28 receptor secreted by the hybridoma and method of using the antibody
Goldberg et al. Immunological effects of high dose administration of anti-CD4 antibody in rheumatoid arthritis patients
Goronzy et al. T-cell co-stimulatory pathways in autoimmunity
US20170058026A1 (en) Methods for modulating immune responses during chronic immune conditions by targeting il-27 induced pathways
EP0607332B1 (fr) Procede prophylactique ou therapeutique de maladies de la peau causees par des cellules presentant des antigenes au moyen d'inhibiteurs de l'interaction entre cd2 et lfa-3
CA2038397A1 (fr) Reactif pour anticorps monoclonal avec nouveau determinant de l'antigene hla sur des molecules du complexe majeur d'histocompatibilite de classe i et methode d'activation des lymphocytes
CA2246352A1 (fr) Procedes d'inhibition d'une reponse immune par blocage des voies de gp39/cd40 et ctla4/cd28/b7 et compositions utilisees avec ceux-ci
Gottlieb et al. Clinical and histologic response to single-dose treatment of moderate to severe psoriasis with an anti-CD80 monoclonal antibody
De Boer et al. Increased expression of adhesion receptors in both lesional and non-lesional psoriatic skin
Guttman-Yassky et al. Blockade of CD11a by efalizumab in psoriasis patients induces a unique state of T-cell hyporesponsiveness
WO2016172417A2 (fr) Interactions entre membres des familles ceacam et tim
Wojciechowski et al. Challenges and opportunities in targeting the costimulation pathway in solid organ transplantation
Schwarz et al. Belatacept/CTLA4Ig: an update and critical appraisal of preclinical and clinical results
WO2002028440B1 (fr) Procedes et compositions servant a moduler l'activation des lymphocytes t et leurs utilisations
US20180298095A1 (en) Interactions between ceacam and tim family members

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: B1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: B1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 10130087

Country of ref document: US

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2423436

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002532264

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002213001

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001981352

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001981352

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001981352

Country of ref document: EP